Format

Send to:

Choose Destination
See comment in PubMed Commons below
Schizophr Res. 2012 Feb;134(2-3):207-10. doi: 10.1016/j.schres.2011.11.009. Epub 2011 Dec 3.

Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial.

Author information

  • 1VA Connecticut Healthcare System, West Haven, CT, USA.

Abstract

OBJECTIVE:

To examine the effect of rimonabant on neurocognitive impairments in people with schizophrenia.

METHODS:

Participants entered a 16-week double-blind, placebo-controlled, randomized clinical trial. A neurocognitive battery was administered at baseline and end of study.

RESULTS:

In comparison to rimonabant (20mg/day), placebo-treated participants exhibited a significant improvement on the Repeatable Battery for the Assessment of Neuropsychological Status total score. In contrast, rimonabant was associated with significant improvement on a probabilistic learning task. There were no other significant treatment effects.

CONCLUSIONS:

Rimonabant did not improve global cognitive functioning, but did improve a specific learning deficit based on response to positive feedback.

Copyright © 2011 Elsevier B.V. All rights reserved.

PMID:
22137462
[PubMed - indexed for MEDLINE]
PMCID:
PMC3268840
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk